The Challenge: Cancer
Cancer incidence worldwide: 19.3 million new cases per year!
The International Agency for Research on Cancer estimates the number of cancer deaths worldwide to be around 9.96 million in 2020.
The number of new cancer cases in the same year was around 19.3 million – and the trend is rising. According to forecasts, the number of cancer deaths could increase to around 16.3 million by 2040.
Moreover a dramatic rise in cancer is observed currently in people under 50.
Cancer is still one of the leading causes of death and morbidity. Therefore one of the major research areas covers new medication as well as the organization of diagnostics and treatment.
SELEQUIN – A Novel Therapy against Hard-to-Treat Carcinomas
A team of chemists and physicians of the Cologne university hospital – the world-renowned Centre for Integrated Oncology – discovered, developed, and patented a group of new compounds that have been shown to work convincingly against cancer both in vitro and in vivo: compounds with blockbuster potential in indications with high hitherto unmet medical need! Several common cancers are still lethal: e.g., lung cancers (both SCLC, NSCLC), Richter’s syndrome in CLL, tumors of the pancreas, glioblastomas, and many more. The new drug has very strong efficacy against several cancers in animal models and in-vitro tests. Until now, the research focused on lung cancers and CLL.
The potential of SELEQUIN and potential back-ups out of the SELEQUIN patent family is very promising in cancer and can grant astounding ROIs. Once confirmed in further studies, the product SELEQUIN has the potential to become a pharmacological blockbuster.